GlassScriptPhysician profile
Emily M Nabors
NPI 1073568200
$8,182.56
in general payments reported to CMS, 2019-2025
42 companies · $1,983 in 2025
The $1,983 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2020: $777 · 2021: $869 · 2022: $800 · 2023: $1,291 · 2024: $1,547 · 2025: $1,983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,820.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,014.27 | 2019-2025 | |
| Novo Nordisk INC | $976.18 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $927.42 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Amgen INC. | $887.15 | 2019-2025 | Repatha, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $443.93 | 2022-2025 | |
| Esperion Therapeutics, INC. | $392.96 | 2021-2025 | Nexletol |
| Pfizer INC. | $325.29 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.14 | 2019-2024 | Jardiance, Synjardy |
| Lilly USA, LLC | $266.38 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $244.67 | 2019-2023 | Verquvo, Belsomra |
| Janssen Pharmaceuticals, INC | $234.36 | 2019-2023 | Spravato |
| Neos Therapeutics, LP | $208.87 | 2019-2024 | Adzenys Xr-Odt |
| Amarin Pharma, INC. | $206.01 | 2019-2023 | |
| Idorsia Pharmaceuticals US INC | $158.16 | 2022-2024 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $156.01 | 2023-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $148.91 | 2024-2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $144.81 | 2019 | |
| Astellas Pharma US INC | $137.77 | 2019-2024 | Veozah |
| Currax Pharmaceuticals LLC | $122.08 | 2023-2025 | Contrave, Nexlizet, Onzetra Xsail |
| Takeda Pharmaceuticals U.S.A., INC. | $114.40 | 2021-2023 | Trintellix |
| Eisai INC. | $78.03 | 2020-2021 | |
| Atland Pharmaceuticals, LLC | $71.50 | 2025 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Otsuka America Pharmaceutical, INC. | $70.18 | 2023-2025 | Rexulti, Nuedexta |
| Tris Pharma INC | $56.49 | 2019-2025 | Dyanavel Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.77 | 2022-2024 | Xifaxan |
| Corcept Therapeutics | $42.91 | 2025 | Korlym |
| Sanofi Pasteur INC. | $42.36 | 2021-2022 | |
| Abbott Laboratories | $41.31 | 2023-2025 | Freestyle Libre 3 |
| Shire North American Group INC | $37.40 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $34.52 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.98 | 2022 | |
| Allergan, INC. | $27.79 | 2020 | |
| Paratek Pharmaceuticals, INC. | $21.69 | 2022 | |
| Ironwood Pharmaceuticals, INC | $19.82 | 2020 | |
| Impel Pharmaceuticals INC. | $19.74 | 2023 | Trudhesa |
| Biohaven Pharmaceuticals, INC. | $18.70 | 2021 | |
| Irhythm Technologies, INC. | $17.64 | 2024 | Zio Xt Patch, Zio Monitor |
| Avanir Pharmaceuticals, INC. | $17.59 | 2022 | |
| Inspire Medical Systems, INC. | $16.96 | 2025 | Inspire |
| Exact Sciences Corporation | $16.60 | 2023 | Cologuard Collection Kit |
| Shield Therapeutics INC | $16.36 | 2023 | Accrufer |
| Glaxosmithkline, LLC. | $14.45 | 2023 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Nabors listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.